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Effects of amyloid and vascular markers
on cognitive decline in subcortical
vascular dementia
ABSTRACT
Objective: To determine the independent and synergistic effects of amyloid and small vessel dis-
ease (SVD) burden on longitudinal cognitive decline in patients with subcortical vascular dementia
(SVaD).
Methods: A longitudinal cohort study was conducted involving patients from outpatient clinics of
2 tertiary referral centers. Sixty-one patients with SVaD were prospectively recruited and under-
went MRI, 11C–Pittsburgh compound B (PiB) PET at baseline, and a 3-year annual neuropsycho-
logical follow-up. Effects of PiB positivity and SVDmarkers (white matter hyperintensities [WMH],
lacunes, and microbleeds) on longitudinal cognitive decline were evaluated using generalized
estimation equation after controlling for age, sex, education, APOE4 allele, and follow-up interval.
Results:When individual neuropsychological tests were used as outcome measures, PiB positivity
was associated with faster cognitive decline in attention, visuospatial, visual memory, and global
cognition function. Higher WMH burden was associated with faster cognitive decline in attention,
visuospatial, visual recognition memory, and semantic/phonemic fluency function, whereas la-
cunes and microbleeds had no significant effects. When global dementia rating (Clinical Dementia
Rating sum of boxes) was considered as an outcome measure, however, only PiB positivity was
associated with faster cognitive decline. Significant interactions between PiB positivity and high-
er SVD burden were found to affect cognitive decline in semantic word fluency (from WMH bur-
den) and global dementia rating (from microbleed burden).
Conclusions: In SVaD patients, amyloid burden, independently or interactively with SVD, contrib-
uted to longitudinal cognitive decline. Amyloid deposition was the strongest poor prognostic
factor. Neurology® 2015;85:1687–1693
GLOSSARY
AD5 Alzheimer disease; AMPETIS5 Amyloid PET Imaging for Subcortical Vascular Dementia; CDR-SOB5Clinical Demen-
tia Rating Sum of Boxes; COWAT 5 Controlled Oral Word Association Test; CVD 5 cerebrovascular disease; DSM-IV 5
Diagnostic and Statistical Manual of Mental Disorders, 4th edition; FLAIR 5 fluid-attenuated inversion recovery; GEE 5
generalized estimation equation; MMSE 5 Mini-Mental State Examination; PiB 5 Pittsburgh compound B; RCFT 5 Rey-
Osterrieth Complex Figure Test; SVaD 5 subcortical vascular dementia; SVD 5 small vessel disease;WMH 5 white matter
hyperintensities.
Small vessel disease (SVD) markers observed in brain MRI in patients with subcortical vascular
dementia (SVaD) include extensive white matter hyperintensities (WMH), lacunar infarcts and
microbleeds.1–6 Recent studies showed that amyloid deposition, a hallmark of Alzheimer disease
(AD), frequently co-occurs with these cerebrovascular disease (CVD) markers in patients with
vascular cognitive impairment.7–9
To date, no longitudinal studies investigating the natural course of cognitive decline in pa-
tients with SVaD have been conducted. Moreover, why some SVaDs take a progressive course
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despite vigorous control of risk factors and
treatment with antiplatelets or anticoagulants
remains largely unanswered. In addition,
although previous studies have shown that
CVD and AD pathologies influence cognitive
dysfunction,10–14 no studies have investigated
the independent effects of CVD and AD
pathologies on cognitive decline in patients
with SVaD.
In the current study, based on a longitudi-
nal cohort study called Amyloid PET Imaging
for Subcortical Vascular Dementia (AMPE-
TIS), we examined the natural course and cog-
nitive trajectories of patients with SVaD in a
3-year follow-up period and investigated the
effects of baseline amyloid burden and SVD
markers on cognitive decline.
METHODS Patients. Participants were prospectively re-
cruited from the memory disorder clinic of Samsung Medical
Center and Asan Medical Center, Seoul, Korea. New or followed
up SVaD patients were asked to participate in the AMPETIS
study from September 2008 to September 2010. All of our SVaD
patients had (1) dementia, (2) focal neurologic signs suggestive of
CVD, and (3) a severe WMH on MRI defined as a cap or band
$10 mm and a deep white matter lesion$25 mm, fulfilling both
DSM-IV vascular dementia criteria15 and the predominantly
white matter cases imaging criteria for SVaD by Erkinjuntti
et al.16 (see e-Methods on the Neurology® Web site at
Neurology.org for details). For longitudinal follow-up, patients
were also required to have (1) 50# age# 85 years and (2) Mini-
Mental State Examination (MMSE) score $10. A total of 121
patients were diagnosed with SVaD, and after those who did not
agree to participate (n5 60) were excluded, 61 participated in the
AMPETIS study. Participants had higher MMSE scores than
nonparticipants (20.7 6 4.9 vs 18.8 6 5.0, p 5 0.033), but
there were no significant differences in demographic features or
Clinical Dementia Rating Sum of Boxes (CDR-SOB). At
baseline, participants underwent brain MRI, Pittsburgh
compound B PET (PiB-PET) scan, and detailed
neuropsychological tests. Afterwards, the participants had 3
serial annual follow-ups with the same neuropsychological tests.
As illustrated in figure 1, of the initial 61 patients with
SVaD, 7 dropped out from the study (dropout rate 11.5%)
for the following reasons: nursing home placement (1/7),
follow-up refusal (3/7), transfer to another hospital (2/7), and
occurrence of cancer (1/7). Among the remaining 54 patients, 6
Figure 1 Flow chart of study participant follow-up
A total of 121 patients were diagnosed with subcortical vascular dementia from September 2008 to September 2010 and
were asked to participate in the Amyloid PET Imaging for Subcortical Vascular Dementia (AMPETIS) study. Sixty-one pa-
tients agreed to participate in the study. During the 3-year follow-up period, 6 patients had cerebral infarction and 7 pa-
tients had a Mini-Mental State Examination (MMSE) score below 10 before their last follow-up. Ten patients dropped out
of the study (dropout rate 16.4%). One patient was admitted to a nursing home; 5 patients refused follow-up; 2 patients
transferred to another hospital; one patient had subdural hematoma; and one patient developed a cancer.
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patients experienced acute cerebral infarctions, 7 patients scored
below 10 on the MMSE (severe cognitive deterioration) during
the follow-up period, and 3 patients died. We did not consider
these 16 patients as dropouts but regarded them as having
reached the endpoint of the current study. Therefore, we
included their neuropsychological data in the analysis obtained
prior to the event (stroke or death). The mean follow-up dura-
tion was 2.58 6 1.02 years (median 2.97 years, interquartile
range 1.99–3.25 years). Among the 7 dropouts, 4 patients had 2
annual follow-ups and 3 had 1 follow-up. The dropout and
remaining patients did not differ in age, sex, education, baseline
MMSE, or baseline CDR-SOB.
During the study period, 59 patients were treated with anti-
platelet agents, 1 with anticoagulants, and 1 patient had a large
unruptured cerebral aneurysm.
Standard protocol approvals, registrations, and patient
consents. We obtained written consent from each participant
and the Institutional Review Board of Asan Medical Center
and Samsung Medical Center approved the study protocol.
Neuropsychological tests. All patients underwent neuropsy-
chological tests using a standardized Seoul Neuropsychological
Screening Battery, which is described in detail elsewhere17,18
and in the e-Methods.
MRI acquisition. All patients were referred to Samsung Medi-
cal Center for MRI using identical imaging protocols on a 3.0T
MRI scanner (Achieva, Philips 3.0T; Eindhoven, Netherlands).
Three-dimensional T1 turbo field echo (TFE), fluid-attenuated
inversion recovery (FLAIR), T1, T2, and fast field echo were
performed on all study participants. Detailed imaging
parameters are described in e-Methods.
Measurement of WMH volume and rating of lacunes and
microbleeds on MRI. We used FLAIR images to quantify
WMH volume through fully automated segmentation and classi-
fication of WMH, as described previously19 and in e-Methods.
Details of lacune and microbleed counting are also described in
e-Methods.
[11C] PiB-PET. [11C] PiB-PET scanning was performed at
Samsung Medical Center or Asan Medical Center using a
Discovery STe PET/CT scanner (GE Medical Systems,
Milwaukee, WI). The detailed methods for PiB-PET scanning
and the calculation of global PiB retention ratio are described in a
previous study9 and in e-Methods. We defined the global PiB
retention ratio as a continuous variable representing amyloid
burden. Patients were considered PiB(1) if their global PiB
retention ratio was more than 2 SDs (PiB retention ratio .1.5)
from the mean of the normal controls.9
Statistical analyses. Descriptive statistics of the baseline
workup were performed using x2 and Student t tests when appro-
priate. To explore the association of SVD markers and PiB reten-
tion with longitudinal changes in neuropsychological scores, the
generalized estimation equation (GEE) was used.20 The GEE
treated individual neuropsychological scores as dependent varia-
bles and the interaction between the follow-up interval from the
baseline and variables including SVD markers and PiB retention
as predictors. Correlation between successive measures in each
patient was accommodated using an unstructured (or
autoregressive) correlation structure. Due to the positive
skewness of SVD markers, we treated them as dichotomized
variables using the second tertile as cutoffs. Patients with SVaD
were therefore divided into higher WMH burden (n 5 21) and
lower WMH burden (n5 40, WMH volume, cutoff, 47 mL);
higher lacunar burden (n 5 23) and lower lacunar burden (n 5
38, number of lacunes , cutoff, 14); and higher microbleed
burden (n 5 20) and lower microbleed burden (n 5 41,
number of microbleeds , cutoff, 7). Comparisons of clinical,
neuropsychological, and MRI characteristics between patients
with higher and lower SVD burden are also summarized in
tables e-1 and e-2.
Two GEE models were applied to determine independent
predictors of longitudinal cognitive decline. In model 1, to test
univariate association between each predictor and longitudinal
cognitive decline, interaction between interval and each indepen-
dent variable was individually tested after controlling for baseline
age, sex, education, APOE4 genotype (APOE4 carrier vs noncar-
rier), and interval (table e-3). Among SVD markers and PiB pos-
itivity, variables interacting with an interval at a p value ,0.1
were selected for the second GEE model (model 2), in which the
selected independent variables were simultaneously entered. In
model 1, possible interaction between PiB positivity and SVD
markers on longitudinal cognitive decline was also tested using 3-
way interaction among PiB positivity, SVD markers, and interval
Table 1 Demographic, clinical, and MRI characteristics of PiB(1) and PiB(2)
patients
Total (n 5 61) PiB(1) (n 5 20) PiB(2) (n 5 41) p Valuea
Female 36 (59.0) 15 (75.0) 21 (51.2) 0.076
Baseline age, y 74.1 6 7.1 79.2 6 3.8 71.7 6 7.0 ,0.001
Disease duration, y 4.8 6 3.7 5.2 6 3.8 4.7 6 3.7 0.603
Education, y 9.3 6 5.1 9.6 6 5.9 9.2 6 4.8 0.774
Risk factors
DM 18 (29.5) 6 (30.0) 12 (29.3) 0.953
HTN 49 (80.3) 17 (85.0) 32 (78.0) 0.734
Hyperlipidemia 25 (41.0) 6 (30.0) 19 (46.3) 0.223
Cardiac disease 8 (13.1) 2 (10.0) 6 (14.6) .0.999
Previous stroke 19 (31.1) 3 (15.0) 16 (39.0) 0.057
Geriatric Depression Scale 16.4 6 8.2 16.4 6 8.2 16.3 6 8.3 0.970
WMH volume, mL 41.7 6 17.7 45.0 6 24.6 40.1 6 13.3 0.318
Number of lacunes 16.3 6 16.8 7.5 6 7.1 20.6 6 18.5 ,0.001
Number of microbleeds 10.0 6 18.3 12.5 6 28.8 8.8 6 10.3 0.588
APOE4 allele, %b 58 20 38 0.006
Carrier 16 (27.6) 10 (50.0) 6 (15.8)
Noncarrier 42 (72.4) 10 (50.0) 32 (84.2)
Hippocampal volume 2.8 6 0.6 2.7 6 0.4 2.9 6 0.6 0.459
Intracranial volume (3103 mL) 1.4 6 0.1 1.4 6 0.2 1.4 6 0.1 0.785
Follow-up information
Incident stroke 6 (9.8) 0 6 (14.6) 0.165
MMSE <10 during follow-up 7 (11.5) 4 (20.0) 3 (7.3) 0.203
Dropout 7 (11.5) 1 (5.0) 6 (14.6) 0.409
Cancer occurrence 1 (1.6) 0 1 (2.4) .0.999
Death 3 (13.1) 2 (10.0) 1 (2.4) 0.248
Abbreviations: DM 5 diabetes mellitus; HTN 5 hypertension; MMSE 5 Mini-Mental State
Examination; PiB 5 Pittsburgh compound B; WMH 5 white matter hyperintensities.
Data are expressed as mean 6 SD or n (%).
ap Values are results of independent t tests or x2 tests.
bAPOE genotypes were analyzed in 58 patients because 3 patients refused the test.
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(table e-4), and those with p , 0.05 were included as predictors
in model 2. Therefore, model 2 tested the independent and inter-
action effect of PiB positivity and SVD markers on longitudinal
cognitive decline. Because GEE model 2 had different predictors
and interaction terms for each neuropsychological test, and in
order to reduce the chances of missing important associations
during the early stage of analysis, we used a statistical significance
level of 0.05 with no correction for multiple comparisons. All
statistical analyses were performed using the Statistical Package
for the Social Sciences 18.0 (SPSS Inc., Chicago, IL).
RESULTS Natural course of SVaD. During the 3-year
follow-up period, 6 patients experienced ischemic
cerebral infarction and all 6 patients were PiB(2).
Among them, 3 patients had territorial infarctions
and the other 3 lacunar infarctions. The MMSE
score was 20.7 6 4.9 at baseline and 18.0 6 6.2
at the third follow-up. The CDR-SOB score was 6.2
6 3.7 at baseline and 8.9 6 5.2 at the third follow-
up. The mean rate of MMSE change was 0.91 per
year and the mean rate of CDR-SOB change was 0.9
per year.
Comparisons of clinical, neuropsychological, and MRI
characteristics and longitudinal cognitive decline between
groups based on PiB positivity and SVD markers. A total
of 20 (32.8%) participants tested positive for PiB
retention. PiB(1) and PiB(2) SVaD groups differed
in terms of age, the number of lacunes, and the pro-
portion of APOE4 carriers (table 1). The PiB(1)
group was older and had a higher proportion of
APOE4 carriers, while the PiB(2) group had a greater
number of lacunes. There were no significant differ-
ences in vascular risk factors.
As illustrated in figure 2, the mean rate of MMSE
decline was 1.63 per year for the PiB(1) SVaD and
0.48 per year for the PiB(2) SVaD group. The mean
rate of CDR-SOB increase was 1.87 per year for the
PiB(1) SVaD and 0.40 per year for the PiB(2) SVaD
group. Figure 2 also illustrates MMSE and CDR-SOB
trajectories according to the higher and lower groups of
each SVD marker. The rates of MMSE decline and
CDR-SOB increase are described in e-Methods.
Effects of amyloid burden and SVD MRI markers on
longitudinal neuropsychological changes. PiB positivity
predicted faster decline in digit span backward, Rey-
Osterrieth Complex Figure Test (RCFT) copy,
RCFT delayed recall, and CDR-SOB scores.
Higher WMH burden was independently associated
with steeper cognitive decline in digit span forward,
Rey copy, RCFT recognition, Controlled Oral
Word Association Test (COWAT) supermarket,
and COWAT phonemic scores, whereas the
Figure 2 Trajectories of cognitive decline over the 3-year follow-up
Trajectories of Mini-Mental State Examination (MMSE) (A) and Clinical Dementia Rating Sum of Boxes (CDR-SOB) (E) for patients with Pittsburgh compound
B (PiB)–positive and PiB-negative subcortical vascular dementia (SVaD) are represented. Trajectories of MMSE and CDR-SOB for patients with higher small
vessel disease (SVD) burden and those with lower SVD burden are also represented for white matter hyperintensities (WMH) (B and F), lacunes (C and G), and
microbleeds (D and H). Circles denote mean values and whiskers represent the 95% confidence intervals for each mean.
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number of lacunes or microbleeds did not affect
cognitive decline.
PiB positivity and higher WMH burden were
interactively associated with faster cognitive decline
in COWAT animal and COWAT supermarket
scores; PiB positivity and higher lacunar burden were
in the immediate recall, delayed recall, and recogni-
tion items of SVLT; and PiB positivity and higher mi-
crobleed burden were in MMSE and CDR-SOB
(table 2). We confirmed these interaction effects by
testing the effect of PiB positivity in the subgroup
with higher SVD burden and in the subgroup with
lower SVD burden, respectively (table e-5).
Sensitivity analysis. First, we used global PiB retention
ratio as a predictor instead of PiB positivity to test the
effect of PiB retention as a continuous variable (table
e-6). The detrimental effect of global PiB retention
ratio was observed in general cognition (MMSE)
and global dementia rating (CDR-SOB).
Data loss ratio was more than 30% at the third
follow-up, and patients with SVaD without the third
follow-up data (see figure 1, n5 9: follow-up loss [4],
death [1], and MMSE ,10 [4]) had more micro-
bleeds than those who completed all the follow-ups
(9.0 6 17.2 vs 24.1 6 28.5, p 5 0.044). We then
performed a sensitivity analysis excluding the third
follow-up data (table e-7). PiB positivity still showed
significant detrimental effects on digit span forward,
Korean version of the Boston Naming Test, MMSE,
and CDR-SOB, but detrimental effect of SVD was
observed only in COWAT animal (from microbleed
burden). Also, the synergistic interaction effect was
observed only in COWAT phonemic (between PiB
positivity and WMH burden) but not in general cog-
nition or global dementia rating.
DISCUSSION The first major finding of our study
was concerned with tracking the natural course of
SVaD. Approximately 10% of the patients experi-
enced cerebral infarction during the 3-year follow-
up, with an equal number of territorial and lacunar
infarction. Interestingly, only PiB(2) patients
developed cerebral infarction. Despite treating
patients with antiplatelet agents or anticoagulants,
no patient developed intracranial macrohemorrhage.
Overall mean rates of MMSE decline in patients with
SVaD was 0.91 per year and CDR-SOB increase was
0.9 per year, which were less steep than those of
patients with AD from our previous study (21.69
per year for MMSE and 1.54 per year for CDR-
SOB).21 However, the rates of decline in MMSE
and CDR-SOB in PiB(1) patients with SVaD
patients were similar to those of patients with AD.
The second major finding was that PiB uptake had
more powerful independent effects on longitudinal
Table 2 Independent and interaction effects of baseline PiB positivity and the
burden of small vessel diseaseMRI markers on neuropsychological change
Neuropsychological test Predictor b (SE) p Value
Digit span forward PiB positivity 20.07 (0.06) 0.221
Higher WMH burden 20.08 (0.02)b 0.002b
Interaction (PiB 3 WMH) 0.12 (0.06) 0.046
Digit span backward PiB positivity 20.09 (0.05)a 0.039a
Higher lacunar burden 0.07 (0.04) 0.085
K-BNT PiB positivity 20.08 (0.05) 0.093
Higher lacunar burden 0.02 (0.03) 0.392
RCFT copy PiB positivity 20.19 (0.08)a 0.024a
Higher WMH burden 20.18 (0.08)b 0.017b
SVLT immediate recall PiB positivity 20.07 (0.08) 0.372
Higher lacunar burden 0.03 (0.06) 0.660
Interaction (PiB 3 lacunar) 20.24 (0.10)c 0.018c
SVLT delayed recall PiB positivity 0.94 (0.23) ,0.001
Higher lacunar burden 20.03 (0.17) 0.881
Interaction (PiB 3 lacunar) 21.70 (0.48)c ,0.001c
SVLT recognition PiB positivity 0.02 (0.04) 0.663
Higher lacunar burden 20.03 (0.03) 0.375
Interaction (PiB 3 lacunar) 20.13 (0.05)c 0.005c
RCFT delayed recall PiB positivity 20.42 (0.21)a 0.046 a
RCFT recognition Higher WMH burden 20.05 (0.02)b 0.006b
COWAT animal PiB positivity 0.05 (0.08) 0.559
Higher WMH burden 20.05 (0.06) 0.384
Interaction (PiB 3 WMH) 20.26 (0.12)c 0.032c
COWAT supermarket PiB positivity 20.05 (0.11) 0.621
Higher WMH burden 20.18 (0.08)b 0.027b
Higher lacunar burden 0.10 (0.06) 0.102
Interaction (PiB 3 WMH) 20.34 (0.16)c 0.033c
COWAT phonemic Higher WMH burden 20.36 (0.10)b ,0.001b
Higher lacunar burden 0.09 (0.07) 0.196
MMSE PiB positivity 20.07 (0.04) 0.088
Higher WMH burden 20.07 (0.04) 0.076
Higher microbleed burden 0.05 (0.03) 0.095
Interaction (PiB 3 microbleed) 20.13 (0.09) 0.139
CDR-SOB PiB positivity 0.13 (0.04)a 0.003a
Higher microbleed burden 20.02 (0.05) 0.607
Interaction (PiB 3 microbleed) 0.17 (0.06)c 0.005c
Abbreviations: CDR-SOB 5 Clinical Dementia Rating Sum of Boxes; COWAT 5 Controlled Oral
Word Association Test; K-BNT5 Korean version of the Boston Naming Test; MMSE5Mini-Mental
State Examination; PiB 5 Pittsburgh compound B; RCFT 5 Rey-Osterrieth Complex Figure Test;
SVLT 5 Seoul Verbal Learning Test; WMH 5 white matter hyperintensities.
Results are a summary of the generalized estimation equations of cognitive change. Covariates
included baseline age, sex, education,APOE4 allele, and follow-up interval from baseline. Predictors
were variables with p, 0.1 in table e-3 and interactions with p, 0.05 in table e-4. The burden of
small vessel disease markers was dichotomized using the second tertile of WMH volume and the
number of lacunes and microbleeds as cutoff values. Regression coefficients (b), standard errors
(SE), and p values for the interaction between predictors and follow-up interval are presented.
aSignificant detrimental effects of PiB positivity, bsmall vessel disease marker, and ctheir
synergistic interaction.
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cognitive decline than SVD markers. Although both
PiB uptake and WMH volume were associated with
cognitive decline when individual cognitive tests were
used as outcome measures, only PiB positivity was
significant when global dementia rating (CDR-
SOB) was considered as an outcome measure. This
finding suggests that relentless cognitive decline in pa-
tients with SVaD despite treatment with antiplatelets
and management of cardiovascular risk factors is pri-
marily driven by additive amyloid burden superim-
posed on vascular burden or their synergistic effects.
Our finding is consistent with a prior study showing
that amyloid burden may be a major determinant of
cognitive impairment overwhelming the effect of
SVD markers in patients with dementia.14 These
findings, therefore, suggest that evaluation of amyloid
deposition may be important when formulating treat-
ment plans for patients with SVaD and anti-amyloid
agents may be needed for treating PiB(1) patients
with SVaD. Conversely, PiB negativity in patients
with SVaD necessitates tight measures of stroke pre-
vention because only PiB(2) patients with SVaD
experienced cerebral infarctions in our study.
Among SVD markers, higher WMH burden was
associated with faster cognitive decline in attention,
visuospatial, visual recognition memory and semantic
fluency scores, but not in global dementia indices.
Previous longitudinal studies involving elderly partic-
ipants without dementia showed that WMH volume
at baseline could predict future cognitive decline, not
only in memory function22 and frontal executive but
also general cognitive function.4 Higher burden of
SVD, further adjustment for amyloid effect, and
inclusion of patients with dementia in our study
could explain the discrepancy of WMH effects on
general cognition between previous studies and our
results.
The third major finding was that PiB uptake and
SVD markers had significant synergistic interaction
such that the effect of amyloid burden and SVD
markers on cognitive decline through an interaction
was greater than the effect of either one added
together. More specifically, PiB positivity and SVD
markers had synergistic interactions for semantic flu-
ency tests and CDR-SOB. Previous preclinical studies
using animal models showed that chronic cerebral hy-
poperfusion and amyloid toxicity interact deleteri-
ously on cognition.23,24 However, all prior human
studies but one25 failed to reveal synergistic interac-
tion between amyloid burden and SVD markers on
cognition.13,26–28 This discrepancy between our study
and most prior studies could be attributed to the fact
that when compared to prior studies, our study was
longitudinal in design and our patients probably
had more severe ischemic changes and cognitive
dysfunction.
Our study has several limitations. First, patients
with SVaD were recruited through a memory clinic.
It is likely that patients with SVaD with predominant
motor symptoms visit a stroke clinic more often than
our memory disorder clinic, and vice versa for patients
with SVaD with predominant cognitive symptoms,
which may limit generalizability of our results. Second,
because we only included the neuropsychological data
obtained prior to stroke, we could not assess the influ-
ence of overt vascular events. Given that stroke
occurred only in the PiB(2) group, the rate of cogni-
tive decline in the PiB(2) group could have been
underestimated. Third, we cannot exclude the possibil-
ity that patients with cerebral amyloid angiopathy have
been included in our sample, although there were only
5 patients who had strictly lobar microbleeds. Fourth,
the cutoff for PiB positivity may be arbitrary. However,
when the global PiB retention ratio was treated as a
continuous variable, the results were largely unchanged
(table e-6). Fifth, data loss ratio at the third follow-up
was significant (more than 30%). This significant
follow-up loss might have resulted in an underestima-
tion of the detrimental effects of SVDmarkers, because
the patients who dropped out at the third follow-up
had more microbleeds than those who completed all
the follow-up. However, when we performed the same
analyses after exclusion of the third follow-up data,
detrimental effects of PiB positivity were still robust,
although detrimental effects of SVD and the synergistic
effect between PiB and SVD markers became less
robust (table e-7). Sixth, because 61 patients with
SVaD who participated in the current study had higher
baseline MMSE scores than 60 patients who did not
agree to participate, we cannot exclude the possibility of
selection bias, which might limit the generalizability of
our results. Finally, since we did not do multiple com-
parison corrections for repeated statistical testing of a
large number of neuropsychological tests, the meaning
of individual tests may be questionable.
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